Q1 2021 Earnings

Revenue

$55M+9.5% YoY

Gross Profit

$35M63.3% margin

Operating Income

$3M5.6% margin

Net Income

$86,0000.2% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

-4.8%

Operating Cash Flow

$21M

Free Cash Flow

$20M

Stock-Based Comp.

$2M

Total Assets

$464M

Total Liabilities

$260M

Stockholders' Equity

$204M

Cash & Equivalents

$25M

Metric	Current	Year Ago	Change
Revenue	$55M	$50M	+9.5%
Gross Profit	$35M	$28M	+23.5%
Operating Income	$3M	-$8M	+138.8%
Net Income	$86,000	-$7M	+101.2%

Sales Of Generic Pharmaceutical Products

$33M57%

Royalties From Licensing Agreements

$11M19%

Sales Of Branded Pharmaceutical Products

$8M13%

Sales Of Contract Manufactured Products

$6M11%

Product Development Services

$158,0000%

Other Revenues

$75,0000%

$53M98%

$1M2%